Interview with Carlos de Sousa, CEO of Immunicum

28 Mar 2017 08:436650

Carlos de Sousa explains the uniqueness and potential of Intuvax, what to expect during the next 12 months and why Immunicum is an attractive investment opportunity.

Read more